Swan Genomics Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
7
Swan Genomics General Information
Description
Operator of a biotechnology company intended to commercialize an approach to DNA sequencing to deliver accessible genomics data. The company uses plasmonic nanoantenna for precision nanoscale sensor positioning at the manufacturing scale, engineered optical hotspot to make single fluorescent molecules thousands of times brighter, and to read bases one at a time as optical pulses in real time from a single molecule, enabling healthcare professionals to get a single platform for accessing the complete molecular picture.
Contact Information
Website
www.swangenomics.comCorporate Office
- Sydney, New South Wales 2075
- Australia
Corporate Office
- Sydney, New South Wales 2075
- Australia
Swan Genomics Timeline
Swan Genomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 01-Aug-2024 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-May-2023 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 01-Jan-2023 | Completed | Generating Revenue |
Swan Genomics Patents
Swan Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026170259-A1 | Systems and methods for analyte processing | Pending | 14-Feb-2025 | ||
| AU-2024903139-A0 | Fluorescence enhancement using quenchers | Pending | 30-Sep-2024 | ||
| WO-2026069007-A2 | Fluorescence enhancement using quenchers | Pending | 27-Sep-2024 | ||
| WO-2026069007-A3 | Fluorescence enhancement using quenchers | Pending | 27-Sep-2024 | ||
| AU-2024267511-A1 | "plasmonic nanoantenna and use of same in single molecule sequencing" | Pending | 08-May-2023 | C12Q1/6869 |
Swan Genomics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EGB Capital (California) | Venture Capital | Minority | ||
| In-Q-Tel | Not-For-Profit Venture Capital | Minority | ||
| Investible | Venture Capital | Minority | ||
| Ki Tua Fund | Corporate Venture Capital | Minority | ||
| Pacific Channel | Venture Capital | Minority |
Swan Genomics FAQs
-
When was Swan Genomics founded?
Swan Genomics was founded in 2023.
-
Where is Swan Genomics headquartered?
Swan Genomics is headquartered in Sydney, Australia.
-
What industry is Swan Genomics in?
Swan Genomics’s primary industry is Biotechnology.
-
Is Swan Genomics a private or public company?
Swan Genomics is a Private company.
-
What is Swan Genomics’s current revenue?
The current revenue for Swan Genomics is .
-
How much funding has Swan Genomics raised over time?
Swan Genomics has raised $2M.
-
Who are Swan Genomics’s investors?
EGB Capital (California), In-Q-Tel, Investible, Ki Tua Fund, and Pacific Channel are 5 of 7 investors who have invested in Swan Genomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process